Poloxamer 188 Copolymer Membrane Sealant Rescues Toxicity of Amyloid Oligomers In Vitro

Journal of Molecular Biology

Volumn 391, Issue 3, 2009, Pages 577-585

  Mina, Erene W ^a   Lasagna Reeves, Cristian ^b   Glabe, Charles G ^a   Kayed, Rakez ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

amyloid; membrane; oligomers; P188; toxicity

Indexed keywords

AMYLOID; OLIGOMER; POLOXAMER;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FETUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID BILAYER; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INTERACTION; RAT;

EID: 67651149466     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.06.024     Document Type: Article

References (50)

1. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J.S., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
2. Caughey B., and Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26 (2003) 267-298
3. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 (2004) 569-580
4. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81 (2003) 678-699
5. Walsh D.M., and Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11 (2004) 213-228
6. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., and Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
7. Porat Y., Kolusheva S., Jelinek R., and Gazit E. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42 (2003) 10971-10977
8. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279 (2004) 46363-46366
9. Canale C., Torrassa S., Rispoli P., Relini A., Rolandi R., Bucciantini M., et al. Natively folded HypF-N and its early amyloid aggregates interact with phospholipid monolayers and destabilize supported phospholipid bilayers. Biophys. J. 91 (2006) 4575-4588
10. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12 (1992) 376-389
11. Mattson M.P. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann. N. Y. Acad. Sci. 747 (1994) 50-76
12. Arispe N., Pollard H.B., and Rojas E. beta-Amyloid Ca(2+)-channel hypothesis for neuronal death in Alzheimer disease. Mol. Cell. Biochem. 140 (1994) 119-125
13. Arispe N., Pollard H.B., and Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid {beta}-protein [A{beta}P-(1-40)] in bilayer membranes. Proc. Natl Acad. Sci. USA 90 (1993) 10573-10577
14. Mirzabekov T., Lin M.C., Yuan W.L., Marshall P.J., Carman M., Tomaselli K., et al. Channel formation in planar lipid bilayers by a neurotoxic fragment of the beta-amyloid peptide. Biochem. Biophys. Res. Commun. 202 (1994) 1142-1148
15. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
16. Hirakura Y., Yiu W.W., Yamamoto A., and Kagan B.L. Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block). Amyloid 7 (2000) 194-199
17. Mirzabekov T.A., Lin M.-C., and Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271 (1996) 1988-1992
18. Kagan B.L., Azimov R.H., and Azimova R. Amyloid peptide channels. J. Membr. Biol. 202 (2004) 1-10
19. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., and Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
20. Green J.D., Kreplak L., Goldsbury C., Li Blatter X., Stolz M., Cooper G.S., et al. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J. Mol. Biol. 342 (2004) 877-887
21. Valincius G., Heinrich F., Budvytyte R., Vanderah D.J., McGillivray D.J., Sokolov Y., et al. Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys. J. 95 (2008) 4845-4861
22. Sokolov Y., Kozak J.A., Kayed R., Chanturiya A., Glabe C., and Hall J.E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol. 128 (2006) 637-647
23. Hannig J., Zhang D., Canaday D.J., Beckett M.A., Astumian R.D., Weichselbaum R.R., and Lee R.C. Surfactant sealing of membranes permeabilized by ionizing radiation. Radiat. Res. 154 (2000) 171-177
24. Tung L., Troiano G.C., Sharma V., Raphael R.M., and Stebe K.J. Changes in electroporation thresholds of lipid membranes by surfactants and peptides. Ann. N. Y. Acad. Sci. 888 (1999) 249-265
25. Lee R.C., Hannig J., Matthews K.L., Myerov A., and Chen C.-T. Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries. Ann. N. Y. Acad. Sci. 888 (1999) 266-273
26. Watanabe M., and Okada T. Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. Mol. Cell. Biochem. 248 (2003) 209-215
27. Serbest G., Horwitz J., and Barbee K. The effect of poloxamer-188 on neuronal cell recovery from mechanical injury. J. Neurotrauma 22 (2005) 119-132
28. Sheldon S.S., and Steinhardt R.A. The mechanisms of cell membrane resealing in rabbit corneal epithelial cells. Curr. Eye Res. 30 (2005) 543-554
29. Frim D.M., Wright D.A., Curry D.J., Cromie W., Lee R., and Kang U.J. The surfactant poloxamer-188 protects against glutamate toxicity in the rat brain. NeuroReport 15 (2004) 171-174
30. Clarke M.S., Prendergast M.A., and Terry Jr. A.V. Plasma membrane ordering agent pluronic F-68 (PF-68) reduces neurotransmitter uptake and release and produces learning and memory deficits in rats. Learn. Mem. 6 (1999) 634-649
31. Schmolka I.R. Physical basis for poloxamer interactions. Ann. N. Y. Acad. Sci. 720 (1994) 92-97
32. Prior S., Gander B., Lecaroz C., Irache J.M., and Gamazo C. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. J. Antimicrob. Chemother. 53 (2004) 981-988
33. Maskarinec S.A., Hannig J., Lee R.C., and Lee K.Y. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys. J. 82 (2002) 1453-1459
34. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
35. Necula M., Kayed R., Milton S., and Glabe C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282 (2007) 10311-10324
36. Dumortier G., Grossiord J.L., Agnely F., and Chaumeil J.C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23 (2006) 2709-2728
37. Kawahara M., Arispe N., Kuroda Y., and Rojas E. Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J. 73 (1997) 67-75
38. Janson J., Ashley R.H., Harrison D., McIntyre S., and Butler P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 (1999) 491-498
39. Ashley R., Harroun T., Hauss T., Breen K., and Bradshaw J. Autoinsertion of soluble oligomers of Alzheimer's Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface. BMC Struct. Biol. 6 (2006) 21
40. Yoshiike Y., Kayed R., Milton S.C., Takashima A., and Glabe C.G. Pore-forming proteins share structural and functional homology with amyloid oligomers. NeuroMolecular Med. 9 (2007) 270-275
41. Hannig J., Yu J., Beckett M., Weichselbaum R., and Lee R.C. Poloxamine 1107 sealing of radiopermeabilized erythrocyte membranes. Int. J. Radiat. Biol. 75 (1999) 379-385
42. Sharma V., Stebe K., Murphy J.C., and Tung L. Poloxamer 188 decreases susceptibility of artificial lipid membranes to electroporation. Biophys. J. 71 (1996) 3229-3241
43. Guohui W., Jaroslaw M., Canay E., Kristian K., Markus Jan W., and Ka Yee C.L. Lipid corralling and poloxamer squeeze-out in membranes. Phys. Rev. Lett. 93 (2004) 028101
44. 2+-regulated exocytosis of lysosomes. Cell 106 (2001) 157-169
45. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
46. Kawahara M., Kuroda Y., Arispe N., and Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J. Biol. Chem. 275 (2000) 14077-14083
47. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3 (2002) 862-872
48. Rapoport N., Marin A.P., and Timoshin A.A. Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch. Biochem. Biophys. 384 (2000) 100-108
49. Marks J.D., Pan C.Y., Bushell T., Cromie W., and Lee R.C. Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection. FASEB J. 15 (2001) 1107-1109
50. Singh-Joy S.D., and McLain V.C. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int. J. Toxicol. 27 Suppl 2 (2008) 93-128